First adjuvanted quadrivalent influenza vaccine by Seqirus receives EU approval


8 June 2020 - The European Commission has today given regulatory approval for the first adjuvanted quadrivalent influenza vaccine to become available across Europe. 

This new vaccine builds on the well-established technology used in an existing adjuvanted trivalent influenza vaccine (aTIV) available in several European countries. aTIV has demonstrated higher effectiveness in people aged 65+ years compared to standard, non-adjuvanted trivalent influenza vaccines.

The new quadrivalent vaccine is specifically designed to protect adults aged 65 and over against four strains of seasonal influenza: two A strains along with two B strains, as opposed to a two A strains and a single B strain in the current vaccine.

Read Seqiris press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Europe , Vaccine , Influenza